Abstract
Alopecia areata is characterized by difficult treatment and easy recurrence, especially posing significant physical and psychological distress to children. However, current treatment options for Pediatric alopecia areata are relatively limited, with generally poor efficacy and numerous side effects. We report the first case of a Pediatric patient transitioning from baricitinib therapy to ritlecitinib, resulting in favorable clinical outcomes. We believe that the result represent a meaningful advance in our understanding of how to treat children with chronic severe AA and feel that this would be of substantial interest to the broad readership of Frontiers in medicine.